Evidence mapPaperPMID 34035524Full record

ArticleNature metabolism2021

Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection.

Laura Montefusco, Moufida Ben Nasr, Francesca D'Addio, Cristian Loretelli, Antonio Rossi, Ida Pastore, Giuseppe Daniele, Ahmed Abdelsalam, Anna Maestroni, Marco Dell'Acqua and 21 more

Abstract read
In one paragraph

Article in Nature metabolism, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 255 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
255citing papers in PubMed, 9 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

255 citing papers in PubMed, 9 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. New-Onset Diabetes Mellitus, Hypertension, Dyslipidaemia as Sequelae of COVID-19 Infection-Systematic Review.International journal of environmental research and public health · 2022
    Pooled it
  9. Pooled it
  10. Trial
  11. Review
  12. Article
  13. Twenty-five years of pediatric type 1 diabetes in Serbia: Trends in age at diagnosis, seasonal variation, and the proportion of diabetic ketoacidosis before, during, and after the COVID-19 pandemic.Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology · 2026
    Article
  14. Article
  15. Leveraging Machine Learning to Assess Post-COVID-19 Glycemic Control in Diabetic Patients.International journal of environmental research and public health · 2026
    Article
  16. Article
  17. Review
  18. Article
  19. Trends of Diabetes in Youth (TrenDY) During COVID-19 Across the United States.The Journal of clinical endocrinology and metabolism · 2026
    Article
  20. Article

195 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

31 authors.

Laura Montefusco *Division of Endocrinology, ASST Fatebenefratelli-Sacco, Milan, Italy.
Moufida Ben Nasr *International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, DIBIC, Università di Milano, Milan, Italy.ORCID http://orcid.org/0000-0002-1022-7853
Francesca D'Addio *International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, DIBIC, Università di Milano, Milan, Italy.
Cristian LoretelliInternational Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, DIBIC, Università di Milano, Milan, Italy.ORCID http://orcid.org/0000-0002-7583-8540
Antonio RossiDivision of Endocrinology, ASST Fatebenefratelli-Sacco, Milan, Italy.
Ida PastoreDivision of Endocrinology, ASST Fatebenefratelli-Sacco, Milan, Italy.ORCID http://orcid.org/0000-0003-0164-3772
Giuseppe DanieleMetabolic Diseases, Department of Medicine, University of Pisa, Pisa, Italy.
Ahmed AbdelsalamInternational Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, DIBIC, Università di Milano, Milan, Italy.ORCID http://orcid.org/0000-0003-3920-4716
Anna MaestroniInternational Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, DIBIC, Università di Milano, Milan, Italy.
Marco Dell'AcquaInternational Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, DIBIC, Università di Milano, Milan, Italy.
Elio IppolitoInternational Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, DIBIC, Università di Milano, Milan, Italy.ORCID http://orcid.org/0000-0003-3770-7205
Emma AssiInternational Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, DIBIC, Università di Milano, Milan, Italy.ORCID http://orcid.org/0000-0002-9363-4234
Vera UsuelliInternational Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, DIBIC, Università di Milano, Milan, Italy.
Andy Joe SeelamInternational Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, DIBIC, Università di Milano, Milan, Italy.ORCID http://orcid.org/0000-0002-4211-5485
Roberta Maria FiorinaInternational Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, DIBIC, Università di Milano, Milan, Italy.
Enrica ChebatDivision of Endocrinology, ASST Fatebenefratelli-Sacco, Milan, Italy.
Paola MorpurgoDivision of Endocrinology, ASST Fatebenefratelli-Sacco, Milan, Italy.
Maria Elena LunatiDivision of Endocrinology, ASST Fatebenefratelli-Sacco, Milan, Italy.
Andrea Mario BollaDivision of Endocrinology, ASST Fatebenefratelli-Sacco, Milan, Italy.
Giovanna FinziDepartment of Pathology, University Hospital ASST-Settelaghi, Varese, Italy.
Reza AbdiRenal Division and Transplantation Research Center, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Joseph V BonventreRenal Division and Transplantation Research Center, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-7144-386X
Stefano RusconiInfectious Diseases Unit, ASST Fatebenefratelli-Sacco, Milan, Italy.ORCID http://orcid.org/0000-0002-0375-9990
Agostino RivaInfectious Diseases Unit, ASST Fatebenefratelli-Sacco, Milan, Italy.ORCID http://orcid.org/0000-0003-3171-3049
Domenico CorradiDepartment of Biomedical, Biotechnological and Translational Sciences, Unit of Pathology, University of Parma, Parma, Italy.ORCID http://orcid.org/0000-0002-8836-4778
Pierachille SantusDivision of Respiratory Diseases, Ospedale L. Sacco, ASST Fatebenefratelli-Sacco, Milan, Italy.
Manuela NebuloniDepartment of Pathology, Papa Giovanni XXIII Hospital, Bergamo, Italy.ORCID http://orcid.org/0000-0002-2773-734X
Franco FolliEndocrinology and Metabolism, Department of Health Science, Università di Milano, ASST Santi Paolo e Carlo, Milan, Italy.
Gian Vincenzo ZuccottiDivision of Endocrinology, ASST Fatebenefratelli-Sacco, Milan, Italy.
Massimo GalliInfectious Diseases Unit, ASST Fatebenefratelli-Sacco, Milan, Italy.
Paolo FiorinaDivision of Endocrinology, ASST Fatebenefratelli-Sacco, Milan, Italy. paolo.fiorina@childrens.harvard.edu.ORCID http://orcid.org/0000-0002-1093-7724

Funding

MECHANISMS OF ISCHEMIC INJURY AND REPAIRR37DK039773 · MASSACHUSETTS GENERAL HOSPITAL · 1993 to 2001
$427k
NIAID NIH HHS K24 AI116925NIDDK NIH HHS R37 DK039773
6 · The paper itself

Abstract

Patients with coronavirus disease 2019 (COVID-19) are reported to have a greater prevalence of hyperglycaemia. Cytokine release as a consequence of severe acute respiratory syndrome coronavirus 2 infection may precipitate the onset of metabolic alterations by affecting glucose homeostasis. Here we describe abnormalities in glycometabolic control, insulin resistance and beta cell function in patients with COVID-19 without any pre-existing history or diagnosis of diabetes, and document glycaemic abnormalities in recovered patients 2 months after onset of disease. In a cohort of 551 patients hospitalized for COVID-19 in Italy, we found that 46% of patients were hyperglycaemic, whereas 27% were normoglycaemic. Using clinical assays and continuous glucose monitoring in a subset of patients, we detected altered glycometabolic control, with insulin resistance and an abnormal cytokine profile, even in normoglycaemic patients. Glycaemic abnormalities can be detected for at least 2 months in patients who recovered from COVID-19. Our data demonstrate that COVID-19 is associated with aberrant glycometabolic control, which can persist even after recovery, suggesting that further investigation of metabolic abnormalities in the context of long COVID is warranted.

Indexed as

Blood GlucoseCohort StudiesCOVID-19HumansHyperglycemiaInsulin ResistanceInsulin-Secreting CellsSARS-CoV-2Blood Glucose

Identifiers

PMID34035524
PMCPMC9931026

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.